ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)